Senior Director, Analytical Development

About Loyal Loyal is a clinical-stage veterinary medicine company developing longevity drugs for dogs. Our mission is to help dogs live longer, healthier lives. We're pioneering a new category of veterinary prescription drugs that proactively and preventatively target the underlying drivers of aging, delaying the onset of disease and preserving quality of life as dogs age. We've already made significant progress in our mission to develop the first FDA-approved drugs to extend canine lifespan: as of early 2026 we've completed two of three major FDA review sections for our lead program, LOY-002, and are targeting submission of the third and final section later this year. Loyal is a well-funded startup with teams of scientists, veterinarians, engineers, operators, and creatives. You'll help us continue on our path of earning FDA approval for the first lifespan extension medicine for any species, and change what's possible for the dogs we love. About the role The Senior Director, Analytical Development provides strategic leadership for all analytical development across Loyal ’s pipeline and future commercial products. This is a hands-on role in a lean, virtual company. You’ll set the strategy and do the work, including authoring the analytical content of CVM submissions.You’ll build and scale the AD organization, leveraging internal and external partners, with deep expertise in OSD analytics and FDA regulatory requirements. You will be reporting to our Vice President of Manufacturing. Your daily work will include Set and execute the global analytical development and quality control strategy aligned with Loyal ’s corporate and CMC objectives. Serve as the accountable executive for GMP analytical operations, ensuring inspection-ready systems, data integrity, PAI readiness at Loyal and CDMOs, and sustained regulatory compliance. Act as a senior CMC leader on cross-functional program teams, influencing development strategy, timelines, and investment decisions. Lead the development, validation, transfer, and lifecycle management of analytical methods and control strategies, with immediate focus on small-molecule oral solid dosage products, while supporting additional modalities as the pipeline evolves. Own the dissolution strategy, including discriminating method development, validation, and the dissolution data package for CVM submissions. Author and review the analytical content of the NADA CMC technical section, including method validation summaries,...

Summary and match are AI-generated; verify details on the original posting.

Listed via Himalayas. All sources